is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to aging and genetic disorders.



the vision

Endogena Therapeutics’ approach for endogenous regenerative medicine will result in a novel treatment paradigm for common degenerative diseases that are becoming more prevalent due to demographic changes.


the mission

Endogena Therapeutics is focusing its drug discovery and development efforts on indications with high unmet medical needs.


endogenous regeneration meets small-molecule medicine

Recent discoveries in stem cell biology together with technological advances for phenotypic, functional screening, have unlocked our ability to harness the potential of adult stem- and progenitor cells. Our novel drug discovery approach is based on the concept of selective regulation of these endogenous cells for controlled tissue repair by small molecules.


In our most advanced programs, we are targeting degenerative diseases of the eye, including retinitis pigmentosa, which progressively leads to complete loss of vision – our pioneering approach enables the discovery of breakthrough therapies based on cutting-edge knowledge of molecular pathways that regulate retinal stem cells and retinal pigment epithelial cells, which nourish the eye’s photoreceptors and retina.


Lead Optimization


Phase I / IIa

Phase III

Age-related macular degeneration
Idiopathic pulmonary fibrosis
Hematopoietic recovery


Lead Optimization


Phase I / IIa

Phase III

Retinitis pigmentosa
age-related macular degeneration
idiopathic pulmonary fibrosis
Hematopoietic recovery

Retinitis pigmentosa (RP)

is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision. Collaborating with leading vitreoretinal specialists and experts in the ophthalmology field, in our most advance program we have initiated clinical studies of our novel treatment paradigm in 2022.

Age-related macular degeneration (AMD)

is a leading cause of irreversible vision loss in the developed world and it has been estimated that almost 9% of the population older than 45 years of age are affected. Dry-AMD is associated with atrophic cell death of the central retina or macula and it accounts for 80-90% of the AMD population. Unfortunately, there is no approved treatment for this condition.

Idiopathic pulmonary fibrosis (IPF)

is a chronic and progressive lung disease, characterized by inflammation and subsequent scarring of the lung that leads to respiratory failure. It is a rare, age-related condition with unknown cause. Every year, 10 out of 100,000 people are diagnosed with this disease, with life expectancy of 3-5 years. Up to date, existing medications only slow down disease progression, therefore there is an urgent need to develop new, more effective and well tolerated drugs for IPF patients.



Retinal Regeneration
10 May 2023
Endogena Therapeutics CEO Matthias Steger discusses fast track FDA approval for EA-2353, a new drug for the treatment of retinitis pigmentosa

Interview the Medicine Maker

Endogena – full enrollment for retinitis pigmentosa trial
4 May 2023

Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa.



Endogena – completed dose escalation study
5 April 2023

Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa


Inherited blindness is almost impossible to treat
27 November 2022

Now there is hope – even if the project of Matthias Steger’s Swiss biotech company still sounds futuristic.
PDF (Translated from the Sonntags Blick-Magazin)

Zwischen Science-Fiction und biblischem Wunder
Vererbte Blindheit lässt sich kaum behandeln. Nun gibt es für Betroffene Hoffnung – auch wenn das Vorhaben eines Schweizer Biotech-Unternehmens noch nach Science-Fiction klingt.

Originalartikel: blick.ch


We work well together, and it shows. We are driven from within, which is in itself – endogenous. Our passionate team loves to discover and develop. Science is at the heart of everything we do and helps us to pursue our purpose.



Endogena’s leadership team is actively supported by a highly knowledgeable Board of Directors with extensive experience in the healthcare industry and capital markets.


Endogena’s shareholders include two anchor investors and a small group of individual investors whose combined support and commitment over the years has been the cornerstone of our success.

Rejuveron Life Sciences AG is a Swiss integrated biotechnology platform company that develops and invests in drugs and technologies which have the potential to improve longevity. As well as providing startup-coaching and incubator lab space, they provide direct investment in promising means to improve health aging, with the ultimate goal of increasing human healthspan.

Rejuveron Life Sciences AG

DEFTA Partners is a technology venture capital firm founded in the 1980s and has offices in San Francisco and Tokyo – DEFTA Healthcare Technologies, the firm’s newly formed fund, invests in seed and early stage companies developing advanced therapeutics and digital health in the USA, Japan, Israel, and beyond – the current investments in healthcare include endogena therapeutics, Orig3n, Two Pore Guys, Lifeguard Health Networks, and Graftworx. DEFTA Partners also supports the annual World Alliance Forum in San Francisco, a premier, international conference focused on game changing healthcare innovations and technologies.

DEFTA Partners

The Centre for Commercialization of Regenerative Medicine (CCRM) is a not-for-profit, public-private consortium supporting the development of foundational technologies that accelerate the commercialization of cell and gene therapies, and regenerative medicine technologies.
These technologies have the potential to transform health care, with the promise to treat, manage and perhaps cure some of the most debilitating and costly diseases in the world today. However, many new potentially life-changing cell, gene and regenerative medicine-based treatments never reach patients because they are not successfully moved from the laboratory to the clinic.
Canadian scientific excellence in stem cells, bioengineering and biomaterials combined with existing infrastructure positions CCRM to coordinate product development and commercialization in a capital-efficient manner.

The Centre for Commercialization of Regenerative Medicine (CCRM)



Endogena is fortunate to have clinical advisors who are at the forefront of ophthalmology, ensuring the successful planning and implementation of Endogena’s programs throughout clinical development.


Endogena’s scientific advisors are scientists, physicians and industry experts who are international key opinion leaders in their fields. They support Endogena’s portfolio programs by providing strategic advice and critical scientific insights.

Prof. Pete Coffey

UCSB / UCL/ Moorfield Eye Hospital

Prof. Andreas Günthe

Prof. Micha Drukker

Stem Cell Biology

Prof. Dr. Gisbert Schneider

Co-Founder / ETH Zürich

Prof. Derek van der Kooy

University of Toronto


open positions

We are a passionate team of diverse scientists aligned around our vision and purpose.
Are you curious to find out more? Do you think you can complement our team?
Please get in touch joinus@endogena.com

expanded policy access

Endogena Therapeutics is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness.

Consistent with Endogena Therapeutic’s mission to bring innovative medicines to patients with serious or life-threatening illnesses or conditions, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible. We are privileged to collaborate with clinical investigators and with patients who participate in our studies to develop new, safe, and effective therapies. We believe this approach will serve patients who could be helped by the therapies we are developing.

However, at the same time, we understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. Because the safety and efficacy of our investigational drugs have not been fully established, Endogena Therapeutics does not normally offer access to our investigational drugs outside of our clinical trials, but rather encourages patients to discuss with their physicians about other disease management options.

On an exceptional basis, Endogena Therapeutics will consider providing a requesting physician with pre-approval access to a specific Endogena Therapeutic investigational drug, for the treatment of an individual patient outside of a clinical trial, when certain conditions are met. These conditions include the following:

  • The patient has a serious or life-threatening illness or condition and is either no longer responsive to or no longer able to tolerate any available treatment option;
  • The investigational drug is in active clinical development with sufficient data available to determine an appropriate dose and schedule for the patient’s specific condition;
  • A benefit-risk analysis, based on both the available clinical data as well as the requesting physician’s assessment of the individual patient’s condition and history, supports making the investigational drug available;
  • The ability of the requesting physician to adequately communicate to the patient the potential risks and benefits of the proposed use of the investigational drug so that the patient can provide informed consent and the willingness of all parties to sign a release;
  • The commitment of the requesting physician to obtain all necessary regulatory and ethical approvals;
  • The likelihood that regulatory authorities and institutional review boards will review and approve expanded access for the patient in a timely basis;
  • Making the investigational drug available will not negatively impact or delay the conduct of clinical trials or regulatory review or approval of the investigational drug for broader patient access;
  • Adequate supply of the investigational drug is available;
  • Other factors we may deem appropriate.

We continually evaluate the benefit-risk profile of each of our investigational drugs based on evolving clinical data. Each compound under development is different and the fact that one investigational drug is made available for the treatment of a particular patient does not mean it will be made available in response to other requests on behalf of other patients whose circumstances and medical histories may be different, or that a different investigational drug will be made available under our policy. Requests will be considered on a case-by-case basis.

Endogena Therapeutics is committed to evaluating all requests in a fair and equitable manner. All requests must be submitted by the patient’s treating physician; Endogena Therapeutics may require more detailed information to fully evaluate a request. The requesting physician must agree to obtain appropriate regulatory and ethics committee approvals and comply with regulatory obligations, including obtaining patient consent, patient monitoring and safety reporting. Each request will be given careful consideration by Endogena Therapeutics whose decisions are final.

Physicians seeking pre-approval access for patients with no alternative treatment options should submit their requests to clinical.studies@endogena.com. We regularly monitor this mailbox and will use our best efforts to acknowledge each submitted request within 10 business days after receipt.

matthias Steger

Matthias Steger’s long career in pharma and biotech began with F. Hoffmann-La Roche in 1999, when he worked in the design and synthesis of active molecules for a variety of therapeutic indications – next, he joined Axovan (later acquired by Actelion), where he built and implemented a new platform for orphan GPCR drug discovery – Matthias then branched out into investment banking at Kepler Equities before returning to Roche in 2007 – he became the firm’s global head of research and technology partnering, a role in which he investigated and managed more than 50 collaborations – in 2015 he followed his strong entrepreneurial instincts, first establishing SequelBlu, an independent advisory firm aimed at assisting companies with sustainable innovation, and then Endogena.
Matthias earned his MSc in organic chemistry and biochemistry at the University of Zurich, and his PhD in medicinal chemistry at the University of Sussex. In 2005 he completed an MBA at the University of St Gallen, where he was awarded Dean’s Honors.


Sven Weiler

Sven Weiler has more than 20 years’ experience in the pharmaceutical industry. After receiving his PhD at the University of Konstanz, Germany he completed his postdoctoral studies at Scripps Resarch Institute, La Jolla, California, USA, working on the total synthesis of complex natural products. In 1999 Sven joined Novartis as a Medicinal Chemistry lab head in the areas of Arthritis and Bone Metabolism. In 2005, as part of an internal talent rotation program, he became Chemistry Project Team Head in the Autoimmunity, Transplantation and Inflammatory (ATI) disease group, working on Sphingosine-1-phosphate receptor agonists. Upon rotation completion, he stepped into the role of Chemistry Unit Head supporting the Novartis Musculoskeletal Disease Area. Prior to joining Endogena Therapeutics and since 2016, Sven has been in the Head of Chemistry role for Basilea Pharmaceutica with a focus on Oncology and Antibacterials. Sven enjoys the interaction with colleagues from different scientific and cultural backgrounds and likes to apply Medicinal Chemistry in a disease-agnostic fashion to tackle medical challenges. 

Moreno Menghini

PD Dr. med. Moreno Menghini is a vitreoretinal specialist with research background in medical retina and imaging. He studied medicine at the University of Zurich, Switzerland, where he gained his MD. Moreno’s clinical training was undertaken at the University Hospital of Zurich, and the Cantonal Hospital of Lucerne, Switzerland. In 2012 he was awarded the George and Rosalie Hearst Fellowship at the University of California, San Francisco, USA to undertake a clinical fellowship under the mentorship of Professor Jacque Duncan. Thereafter he worked for a Swiss private eye clinic before having been granted 2016 the position of vitreoretinal fellow at Sir Charles Gairdner Hospital in Perth, Australia, where he trained under the supervision of Professor Ian Constable. In 2019, Dr. Menghini completed an academic fellowship with focus on retinal gene therapy at the University of Oxford, UK under the mentorship of Professor Robert MacLaren. As an honorary clinical research associate of the University of Oxford, he continues to be involved scientifically through various joint collaborations. Through his continuous academic achievements Dr. Menghini has recently received the venia legendi at the University of Zurich, and holds the title of “Privat Dozent”. In January 2021, Dr. Menghini was nominated Head of Department of Ophthalmology at the Ospedale Regionale di Lugano, Switzerland, and is now also responsible for the ophthalmology teaching module at the medical school of the Università Svizzera Italiana (USI). Furthermore, Dr. Menghini is adjoint consultant ophthalmologist at the Eye Clinic of the Luzerner Kantonsspital (LUKS), Lucerne, Switzerland, where he holds a monthly retinal dystrophy and oculogenetics clinic.

Michael lai

Michael is a specialist pharmaceutical physician with over 20 years of clinical research experience in the industry. He has been involved in the clinical development of therapies in diverse therapeutic areas, including ophthalmology, cardiology, immunology and infectious diseases, and has supported successful registrations in the US, EU, China, Japan and Australia.

Michael obtained his medical degree from the University of Western Australia, his MBA from the Australian Graduate School of Management and is a Fellow of the Faculty of Pharmaceutical Medicine in the UK.

Daphna Mokady

Daphna Mokady is a science-innovation and results-driven professional with 15+ years of academic and industry experience in leading research projects in a broad spectrum of biomedical fields, including regenerative medicine, cancer research, neurodegenerative disease modelling, and microbiology. Her versatile experience enables her to promote innovative ideas and lead pioneering research with demonstrated results. Throughout her work, Daphna cultivated a network of successful collaborations with global pharmaceutical companies, top researchers, and key opinion leaders in various fields. She is a passionate advocate of gender equality in STEM and the founder and president of a Toronto-based initiative aimed at promoting women’s careers in all STEM disciplines up to the boardroom.

Daphna holds a PhD in Microbiology from Tel Aviv University and an MSc (summa cum laude) in Genetics from the Hebrew University of Jerusalem.

Manfred Schneider

Manfred Schneider is a certified toxicologist and ADME/PK specialist with almost 25 years of broad-based experience in various fields of pharmaceutical R&D. Since 2013, he is a consultant for several large and small pharmaceutical companies with a strong proven track record, in particular, >10 recent successful small-molecule nonclinical safety packages and the subsequent bioanalytical and PK evaluation of the clinical trials up to Phase II.

Manfred received his PhD in Chemistry from the University of Ulm in Germany and holds a US board certification as toxicologist (DABT). Following a molecular toxicology postdoc at UC Berkeley, Manfred worked at Tularik, Forest Laboratories, was head of early ADME at Merck Serono, and head of DMPK & TOX at Addex.

Susanne Raab

Susanne Raab is an accomplished in vivo pharmacology leader in drug discovery and development research. She has a solid track record of successful contributions to the R&D pipeline, advancing projects through development to clinical proof of concept. Susanne has worked at Roche for over 17 years as in vivo pharmacologist as well as project leader in different therapeutic areas. Susanne was in charge of in vivo pharmacology in the ophthalmology group at Roche, whereby she advanced candidates to clinical proof of concept. She was further involved in the planning, leading and managing of outsourcing activities with CROs and academic collaborators worldwide.

Susanne holds a MSc and PhD in Agricultural Biology from the University of Hohenheim in Germany and a Diploma in Medicines Development Sciences. Her main research focus lies on ophthalmological, cardiovascular and metabolic diseases.

Daniel Froehlich

Daniel Froehlich has more than 25 years of experience in different areas of accounting, finance, and controlling. His long career started in stock market-listed Swiss multinational groups, where – with increased responsibilities – he held various leadership roles in operations, finance, and controlling. Subsequently, Daniel changed into a regional finance function for a global industry business. Prior to joining Endogena Therapeutics in 2023, Daniel served as CFO and COO of an SME entity in the MedTech industry for more than 10 years. As a member of the Executive Board, he was involved in the execution of strategic projects.

Daniel graduated from the University of Applied Sciences in Economic and Business Administration, Zuerich, Switzerland. In 2009, he completed his Master of Advanced Studies in Controlling at the Institute for Financial Services Zug IFZ, Switzerland.

Giuseppe Marco Randazzo

Marco Randazzo is a cheminformatic data scientist with a research background in chemistry, machine-learning (ML), and cheminformatics applied in drug discovery. He has developed ML and cheminformatics tools for automatic compound annotation in metabolomics approach at the University of Geneva. Giuseppe Marco also worked in a joint venture between the University of Geneva and a private industrial partner Firmenich, delivering new active nature-identical compounds. He also worked for the Dalle Molle Institute for Artificial Intelligence (IDSIA) and later for Hoffmann-La Roche, implementing new AI methods for drug discovery. Marco completed his Ph.D. in chemical science at the laboratory of chemometrics and cheminformatic University of Perugia (Italy).

Christiane Hyvert

Christiane Hyvert joined Endogena in 2022. With a background in communications and sales & marketing, and after spending several years living and working in big European & American cities, Christiane gained broad experience in human resources while working at Novartis. Her expertise covers leadership development, talent management, business partnering, employee engagement, diversity and inclusion and organizational development.

Christiane holds a MA in Communications from the University of Zürich, a MAS Human Resources Leadership from the HWZ Hochschule für Wirtschaft Zürich and is an accredited agile coach.  She is passionate about HR and healthcare and is an Alumni of the Woman Back to Business Program at the University of St.Gallen (HSG).

Jason Charish

Jason Charish is an experienced molecular biology / bio-medical researcher who is passionate about translating insights on eye and central nervous system pathology into new treatments. During his MSc, PhD (University of Toronto) and subsequent post-doctoral work (University Health Network), he gained expertise in numerous models of human diseases, with an emphasis on the retina. His MSc work provided insight into how the eye and brain develops, while his PhD established that the same molecular pathways guiding normal development can become dysregulated in various disease states in the adult. His work has been published in leading academic journals including the Journal of Clinical Investigation, Nature Chemical Biology, Cell Death & Differentiation, among many others. Throughout this time, he has established numerous successful cross-disciplinary collaborations with both academic groups and pharmaceutical companies.

Arturo Ortin Martinez

Arturo Ortin Martinez is a retina researcher with 15 years of experience in the experimental ophthalmology field. After completing an MSc in Vision Science through an international program, Arturo graduated from the University of Murcia (Spain) with a PhD with a Cum Laude qualification and International Mention. He was also awarded the “Extraordinary Doctorate” Prize for his thesis in neurodegeneration and neuroprotection of the retina. After moving to Toronto, Arturo received a postdoctoral joint fellowship from the Ontario Institute of Regenerative Medicine, University of Toronto’s Medicine by Design initiative, and the Foundation Fighting Blindness Canada. During this period, Arturo led and managed a dedicated group of researchers at the Wallace Lab in exploring the therapeutic potential of photoreceptors transplantation in retinal degeneration. This period culminated in a pivotal discovery that shifted the paradigm of the photoreceptor transplantation mediating vision rescue. 

Arturo’s extensive academic work has contributed to advancing our understanding of the cellular and molecular foundations of retinal pathologies and developing novel therapeutic strategies for fighting them. Recently, Arturo joined the Endogena Team, extremely motivated to help develop novel therapeutics. Through advanced projects and initiatives for Endogena Therapeutics, he hopes to help millions of people living with progressive vision loss and blindness.

Mariana Oliveira

Mariana Oliveira is a biomedical science researcher with physiology and cellular biology background. During her M.Sc. and Ph.D., Mariana participated in studies testing potential treatments for metabolic and neurologic diseases, working together with different pharmaceutical companies. With a passion for learning and collaborating with others, she has participated in many exciting projects during her time at the Université de Montréal. Being skilled with in vivo and in vitro models, Mariana has developed a surgical model of metabolic disease in female animals, explored the function and natural pathways of specific enzymes in the blood-brain barrier and the impact of systemic insults in the central nervous system.

Johanna Vunder

Johanna Vunder has a proven track record in executing clinical trials on time, within budget, with full oversight. During her work for Novartis and PRA Health Silences, she gained experience in international phase II-IV trials. She was exposed to a broad array of operational tasks, such as: regulatory submissions, trial document creation, trial budget planning and negotiation, site selection, trial monitoring and management. Her indication expertise covers neurology, cardiology, dermatology, oncology, ophthalmology, and renal & metabolic diseases. Johanna studied at the Karolinska Institute in Stockholm and King’s College London for her BSc in Biomedicine, and she holds a MSc in Neurobiology from the University of Zürich.

Mike Tanji

Mike Tanji is an esteemed board member with a distinguished career that spans multiple industries and includes significant experience in the Asian market and in the global market. Starting his journey at The Long-Term Credit Bank of Japan, Ltd. (LTCB), followed by the secondment to the Ministry of International Trade and Industry in Japan, Mike gained invaluable expertise in the financial sector. Subsequent to his time at LTCB, he held key positions, including Senior Consultant at Jomon Associates, Executive Assistant to the President at Shin Ginko Tokyo Co., Ltd., and Senior Managing Executive Officer at Aruze Corporation. With an in-depth understanding of the Asian and global markets, Mike played a crucial role in supporting corporate customers’ entry into Asian countries as well as management in the global market. Currently, he serves as the COO of DEFTA Partners and the President & CEO of Bacchus Bio Innovation Co., Ltd., leveraging his regional and global knowledge to drive growth and forge strategic partnerships. Mike’s role as a Director at the Alliance Forum Foundation showcases his commitment to initiatives promoting positive social and economic progress.

With a Juris Doctor degree and a Directorship at Japan Initiative, complemented by his global market experience, Mike brings a diverse skill set to his board position. His breadth of knowledge and strategic acumen make him a vital asset to our organization.

Dan Zabrowski

Dan is a part-time Venture Partner at Decheng Capital.  Prior to joining Decheng, Dan worked over 20 years for Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. During his tenure in Business Development and Diagnostics, Dr. Zabrowski and his teams delivered 300+ acquisition and partnership deals. In addition, he was Board member of Chugai Pharmaceuticals. Prior to joining Roche, Dan worked at Syntex, Fujisawa (now Astellas) and G.D. Searle in their pharmaceutical R&D organizations and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois — Chicago.

Dan received his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.

Oliver Colville

Oliver is a Biotechnology Associate at the Apeiron Investment Group, the $3bn AUM family office of Christian Angermayer. At Apeiron Oliver works closely with biotech companies in the existing portfolio, including as a Board Observer at Alto Neuroscience and closely with Rejuveron Lifesciences, aiding strategy and operations. Prior to joining Apeiron, Oliver interned with Fountain Healthcare Partners, an Irish life science VC fund with $310m AUM, where he was responsible for scientific and technical due diligence, including FHP’s investment in Calypso Biotech. Additionally, Oliver worked for several years as an Analyst/Associate at Torreya, a global life science investment bank, where he worked on multiple public and private transactions across biopharma (ophthalmology, oncology, and gene therapy) and services, highlights of which include raising equity capital for SparingVision and the sale of Cobra Biologics to Cognate Bioservices. 

Oliver holds a research MSc in Cancer Biology (Distinction) from Imperial College London, and a BSc degree in Pharmacology (honours) from Newcastle University.

Brian Ballios


Assistant Professor, University of Toronto Clinician-Scientist, University Health Network Staff Ophthalmologist, University Health Network, Sunnybrook Health Sciences Centre, and Kensington Vision & Research Centre Scientist, Krembil Research Institute

Sandrine Zweifel

PD Dr med FEBO
FMH Ophth / Ophth Surg

Vice Chair Department of Ophthalmology, University Hospital Zürich, University Zürich

Mark Pennesi


Kenneth C. Swan Endowed Professor of Ophthalmology
Professor of Molecular and Medical Genetics Chief, Paul H. Casey Ophthalmic Genetics Division Casey Eye Institute Oregon Health & Science University

Karl CsaKY


T. Boone Pickens Director
Molecular Ophthalmology Laboratory
Director, Clinical Center of Innovation for AMD
Chief Executive and Medical Officer
Retina Foundation of the Southwest

Giovanni Staurenghi


Professor of Ophthalmology and Chairman of the University Eye Clinic
Director of the University Eye Clinic Department of Biomedical and Clinical Science Luigi Sacco Hospital, Milan

David Sarraf


Clinical Professor of Ophthalmology, Stein Eye Institute, UCLA

Glenn yiu


Professor of Ophthalmology, University of California, Davis Health